FOXP3 orchestrates H4K16 acetylation and H3K4 trimethylation for activation of multiple genes by recruiting MOF and causing displacement of PLU-1

Molecular Cell

Volumn 44, Issue 5, 2011, Pages 770-784

  Katoh, Hiroto ^a   Qin, Zhaohui S ^b   Liu, Runhua ^a   Wang, Lizhong ^a   Li, Weiquan ^a   Li, Xiangzhi ^a   Wu, Lipeng ^a   Du, Zhanwen ^c   Lyons, Robert ^a,d   Liu, Chang Gong ^e   Liu, Xiuping ^e   Dou, Yali ^a   Zheng, Pan ^a   Liu, Yang ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b EMORY UNIVERSITY   (United States)

^c INSTITUTE OF BIOPHYSICS   (China)

^d UNIVERSITY OF MICHIGAN   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE MOF; HISTONE DEMETHYLASE; HISTONE DEMETHYLASE PLU 1; HISTONE H3; HISTONE H4; RNA; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; BINDING SITE; CONTROLLED STUDY; EPIGENETICS; GENE ACTIVATION; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PROSTATE EPITHELIUM; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MICROARRAY; RNA INTERFERENCE; SOMATIC MUTATION; TRANSCRIPTION INITIATION; TRIMETHYLATION;

ACETYLATION; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; HEK293 CELLS; HISTONE ACETYLTRANSFERASES; HISTONES; HUMANS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; METHYLATION; MUTATION; NUCLEAR PROTEINS; REPRESSOR PROTEINS;

EID: 83455225616     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2011.10.012     Document Type: Article

References (60)

1. Bennett C.L., Christie J., Ramsdell F., Brunkow M.E., Ferguson P.J., Whitesell L., Kelly T.E., Saulsbury F.T., Chance P.F., Ochs H.D. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 2001, 27:20-21.
2. Birzele F., Fauti T., Stahl H., Lenter M.C., Simon E., Knebel D., Weith A., Hildebrandt T., Mennerich D. Next-generation insights into regulatory T cells: expression profiling and FoxP3 occupancy in Human. Nucleic Acids Research 2011, 39:7946-7960.
3. Brunkow M.E., Jeffery E.W., Hjerrild K.A., Paeper B., Clark L.B., Yasayko S.A., Wilkinson J.E., Galas D., Ziegler S.F., Ramsdell F. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 2001, 27:68-73.
4. Cartharius K., Frech K., Grote K., Klocke B., Haltmeier M., Klingenhoff A., Frisch M., Bayerlein M., Werner T. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005, 21:2933-2942.
5. Chatila T.A., Blaeser F., Ho N., Lederman H.M., Voulgaropoulos C., Helms C., Bowcock A.M. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J. Clin. Invest. 2000, 106:R75-R81.
6. Chi P., Allis C.D., Wang G.G. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 2010, 10:457-469.
7. Dalgliesh G.L., Furge K., Greenman C., Chen L., Bignell G., Butler A., Davies H., Edkins S., Hardy C., Latimer C., et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010, 463:360-363.
8. Dion M.F., Altschuler S.J., Wu L.F., Rando O.J. Genomic characterization reveals a simple histone H4 acetylation code. Proc. Natl. Acad. Sci. USA 2005, 102:5501-5506.
9. Dou Y., Milne T.A., Tackett A.J., Smith E.R., Fukuda A., Wysocka J., Allis C.D., Chait B.T., Hess J.L., Roeder R.G. Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell 2005, 121:873-885.
10. Duns G., van den Berg E., van Duivenbode I., Osinga J., Hollema H., Hofstra R.M., Kok K. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res. 2010, 70:4287-4291.
11. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 2003, 4:330-336.
12. Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., Bonaldi T., Haydon C., Ropero S., Petrie K., et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 2005, 37:391-400.
13. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
14. Jenuwein T., Allis C.D. Translating the histone code. Science 2001, 293:1074-1080.
15. Katoh H., Zheng P., Liu Y. Signalling through FOXP3 as an X-linked tumor suppressor. Int. J. Biochem. Cell Biol. 2010, 42:1784-1787.
16. Kleer C.G., Cao Q., Varambally S., Shen R., Ota I., Tomlins S.A., Ghosh D., Sewalt R.G., Otte A.P., Hayes D.F., et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. USA 2003, 100:11606-11611.
17. Kwon S.Y., Xiao H., Wu C., Badenhorst P. Alternative splicing of NURF301 generates distinct NURF chromatin remodeling complexes with altered modified histone binding specificities. PLoS Genet. 2009, 5:e1000574.
18. Ladoire S., Arnould L., Mignot G., Coudert B., Rébé C., Chalmin F., Vincent J., Bruchard M., Chauffert B., Martin F., et al. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res. Treat. 2011, 125:65-72.
19. Lee K.K., Workman J.L. Histone acetyltransferase complexes: one size doesn't fit all. Nat. Rev. Mol. Cell Biol. 2007, 8:284-295.
20. Lee J.S., Smith E., Shilatifard A. The language of histone crosstalk. Cell 2010, 142:682-685.
21. Levy D., Gozani O. Decoding chromatin goes high tech. Cell 2010, 142:844-846.
22. Li X., Dou Y. New perspectives for the regulation of acetyltransferase MOF. Epigenetics 2010, 5:185-188.
23. Li B., Samanta A., Song X., Iacono K.T., Bembas K., Tao R., Basu S., Riley J.L., Hancock W.W., Shen Y., et al. FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc. Natl. Acad. Sci. USA 2007, 104:4571-4576.
24. Li X., Corsa C.A., Pan P.W., Wu L., Ferguson D., Yu X., Min J., Dou Y. MOF and H4 K16 acetylation play important roles in DNA damage repair by modulating recruitment of DNA damage repair protein Mdc1. Mol. Cell. Biol. 2010, 30:5335-5347.
25. Liu R., Wang L., Chen G., Katoh H., Chen C., Liu Y., Zheng P. FOXP3 up-regulates p21 expression by site-specific inhibition of histone deacetylase 2/histone deacetylase 4 association to the locus. Cancer Res. 2009, 69:2252-2259.
26. Liu Y., Wang L., Zheng P. X-linked tumor suppressors: perplexing inheritance, a unique therapeutic opportunity. Trends Genet. 2010, 26:260-265.
27. Lu C., Han H.D., Mangala L.S., Ali-Fehmi R., Newton C.S., Ozbun L., Armaiz-Pena G.N., Hu W., Stone R.L., Munkarah A., et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 2010, 18:185-197.
28. Marson A., Kretschmer K., Frampton G.M., Jacobsen E.S., Polansky J.K., MacIsaac K.D., Levine S.S., Fraenkel E., von Boehmer H., Young R.A. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007, 445:931-935.
29. Martin C., Zhang Y. The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell Biol. 2005, 6:838-849.
30. Mikkelsen T.S., Ku M., Jaffe D.B., Issac B., Lieberman E., Giannoukos G., Alvarez P., Brockman W., Kim T.K., Koche R.P., et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 2007, 448:553-560.
31. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6:38-51.
32. Mosammaparast N., Shi Y. Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases. Annu. Rev. Biochem. 2010, 79:155-179.
33. Pan G., Tian S., Nie J., Yang C., Ruotti V., Wei H., Jonsdottir G.A., Stewart R., Thomson J.A. Whole-genome analysis of histone H3 lysine 4 and lysine 27 methylation in human embryonic stem cells. Cell Stem Cell 2007, 1:299-312.
34. Pan F., Yu H., Dang E.V., Barbi J., Pan X., Grosso J.F., Jinasena D., Sharma S.M., McCadden E.M., Getnet D., et al. Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science 2009, 325:1142-1146.
35. Pfister S., Rea S., Taipale M., Mendrzyk F., Straub B., Ittrich C., Thuerigen O., Sinn H.P., Akhtar A., Lichter P. The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma. Int. J. Cancer 2008, 122:1207-1213.
36. Qin Z.S., Yu J., Shen J., Maher C.A., Hu M., Kalyana-Sundaram S., Yu J., Chinnaiyan A.M. HPeak: an HMM-based algorithm for defining read-enriched regions in ChIP-Seq data. BMC Bioinformatics 2010, 11:369.
37. Robinson P.J., An W., Routh A., Martino F., Chapman L., Roeder R.G., Rhodes D. 30 nm chromatin fibre decompaction requires both H4-K16 acetylation and linker histone eviction. J. Mol. Biol. 2008, 381:816-825.
38. Ruthenburg A.J., Allis C.D., Wysocka J. Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Mol. Cell 2007, 25:15-30.
39. Ruthenburg A.J., Li H., Milne T.A., Dewell S., McGinty R.K., Yuen M., Ueberheide B., Dou Y., Muir T.W., Patel D.J., Allis C.D. Recognition of a mononucleosomal histone modification pattern by BPTF via multivalent interactions. Cell 2011, 145:692-706.
40. Sadlon T.J., Wilkinson B.G., Pederson S., Brown C.Y., Bresatz S., Gargett T., Melville E.L., Peng K., D'Andrea R.J., Glonek G.G., et al. Genome-wide identification of human FOXP3 target genes in natural regulatory T cells. J. Immunol. 2010, 185:1071-1081.
41. Sawasdichai A., Chen H.T., Abdul Hamid N., Jayaraman P.S., Gaston K. In situ subcellular fractionation of adherent and non-adherent mammalian cells. J. Vis. Exp. 2010, 41:e1958. 10.3791/1958.
42. Scibetta A.G., Santangelo S., Coleman J., Hall D., Chaplin T., Copier J., Catchpole S., Burchell J., Taylor-Papadimitriou J. Functional analysis of the transcription repressor PLU-1/JARID1B. Mol. Cell. Biol. 2007, 27:7220-7235.
43. Shi Y., Whetstine J.R. Dynamic regulation of histone lysine methylation by demethylases. Mol. Cell 2007, 25:1-14.
44. Shi Y., Lan F., Matson C., Mulligan P., Whetstine J.R., Cole P.A., Casero R.A., Shi Y. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004, 119:941-953.
45. Shogren-Knaak M., Ishii H., Sun J.M., Pazin M.J., Davie J.R., Peterson C.L. Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science 2006, 311:844-847.
46. Smith E.R., Cayrou C., Huang R., Lane W.S., Côté J., Lucchesi J.C. A human protein complex homologous to the Drosophila MSL complex is responsible for the majority of histone H4 acetylation at lysine 16. Mol. Cell. Biol. 2005, 25:9175-9188.
47. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature 2000, 403:41-45.
48. Taipale M., Rea S., Richter K., Vilar A., Lichter P., Imhof A., Akhtar A. hMOF histone acetyltransferase is required for histone H4 lysine 16 acetylation in mammalian cells. Mol. Cell. Biol. 2005, 25:6798-6810.
49. Vastenhouw N.L., Zhang Y., Woods I.G., Imam F., Regev A., Liu X.S., Rinn J., Schier A.F. Chromatin signature of embryonic pluripotency is established during genome activation. Nature 2010, 464:922-926.
50. Vermeulen M., Eberl H.C., Matarese F., Marks H., Denissov S., Butter F., Lee K.K., Olsen J.V., Hyman A.A., Stunnenberg H.G., Mann M. Quantitative interaction proteomics and genome-wide profiling of epigenetic histone marks and their readers. Cell 2010, 142:967-980.
51. Wang L., Liu R., Li W., Chen C., Katoh H., Chen G.Y., McNally B., Lin L., Zhou P., Zuo T., et al. Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell 2009, 16:336-346.
52. Wang Z., Zang C., Cui K., Schones D.E., Barski A., Peng W., Zhao K. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 2009, 138:1019-1031.
53. Wang L., Liu R., Ribick M., Zheng P., Liu Y. FOXP3 as an X-linked tumor suppressor. Discov. Med. 2010, 10:322-328.
54. Wildin R.S., Ramsdell F., Peake J., Faravelli F., Casanova J.L., Buist N., Levy-Lahad E., Mazzella M., Goulet O., Perroni L., et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 2001, 27:18-20.
55. Wysocka J., Swigut T., Xiao H., Milne T.A., Kwon S.Y., Landry J., Kauer M., Tackett A.J., Chait B.T., Badenhorst P., et al. A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling. Nature 2006, 442:86-90.
56. Yamane K., Tateishi K., Klose R.J., Fang J., Fabrizio L.A., Erdjument-Bromage H., Taylor-Papadimitriou J., Tempst P., Zhang Y. PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol. Cell 2007, 25:801-812.
57. Yu J., Yu J., Mani R.S., Cao Q., Brenner C.J., Cao X., Wang X., Wu L., Li J., Hu M., et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010, 17:443-454.
58. Zheng Y., Josefowicz S.Z., Kas A., Chu T.T., Gavin M.A., Rudensky A.Y. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 2007, 445:936-940.
59. Zuo T., Liu R., Zhang H., Chang X., Liu Y., Wang L., Zheng P., Liu Y. FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J. Clin. Invest. 2007, 117:3765-3773.
60. Zuo T., Wang L., Morrison C., Chang X., Zhang H., Li W., Liu Y., Wang Y., Liu X., Chan M.W., et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 2007, 129:1275-1286.